Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy

Science Translational Medicine

Volumn 7, Issue 310, 2015, Pages

  Li, Rui ^a   Rezk, Ayman ^a   Miyazaki, Yusei ^a   Hilgenberg, Ellen ^b   Touil, Hanane ^a   Shen, Ping ^b   Moore, Craig S ^a   Michel, Laure ^c   Althekair, Faisal ^a   Rajasekharan, Sathy ^a   Gommerman, Jennifer L ^d   Prat, Alexandre ^a   Fillatreau, Simon ^b   Bar Or, Amit ^a  

^a MCGILL UNIVERSITY   (Canada)

^b DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; STAT5 PROTEIN; STAT6 PROTEIN; AUTACOID;

ARTICLE; B CELL DEPLETION THERAPY; BONE MARROW CELL; CELL ACTIVATION; CELL THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LYMPHOCYTE COUNT; MEMORY CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; B LYMPHOCYTE; BIOSYNTHESIS; CHEMISTRY; LYMPHOCYTE DEPLETION; METABOLISM; PATHOLOGY;

B-LYMPHOCYTES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFLAMMATION MEDIATORS; LYMPHOCYTE DEPLETION; MULTIPLE SCLEROSIS;

EID: 84945538148     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aab4176     Document Type: Article

References (33)

1. R. Stasi, A. Pagano, E. Stipa, S. Amadori, Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98, 952-957 (2001).
2. S. B. Cohen, P. Emery, M. W. Greenwald, M. Dougados, R. A. Furie, M. C Genovese, E. C Keystone, J. E. Loveless, G.-R. Burmester, M. W. Cravets, E. W. Hessey, T. Shaw, M. C. Totoritis; REFLEX Trial Group, Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54, 2793-2806 (2006).
3. S. L Hauser, E. Waubant, D. L Arnold, T. Vollmer, J. Antel, R. J. Fox, A. Bar-Or, M. Panzara, N. Sarkar, S. Agarwal, A. Langer-Gould, C H. Smith; HERMES Trial Group, B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676-688 (2008).
4. A. Bar-Or, P. A. J. Calabresi, D. Arnold, C Markowitz, S. Shafer, L. H. Kasper, E. Waubant, S. Gazda, R. J. Fox, M. Panzara, N. Sarkar, S. Agarwal, C H. Smith, Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial. Ann. Neurol. 63, 395-400 (2008).
5. R. T. Naismith, L. Piccio, J. A. Lyons, J. Lauber, N.T. Tutlam, B.J. Parks, K. Trinkaus, S. K. Song, A. H. Cross, Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial. Neurology 74, 1860-1867 (2010).
6. L. Kappos, D. Li, P. A. Calabresi, P. O'Connor, A. Bar-Or, F. Barkhof, M.Yin, D. Leppert, R. Glanzman, J. Tinbergen, S. L. Hauser, Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378, 1779-1787 (2011).
7. J. A. Gómez-Puerta, L. F. Quintana, J. H. Stone, M. Ramos-Casals, X. Bosch, B-cell depleting agents for ANCA vasculitides: A new therapeutic approach. Autoimmun. Rev. 11, 646-652 (2012).
8. P. S. Sorensen, S. Lisby, R. Grove, F. Derosier, S. Shackelford, E. Havrdova, J. Drulovic, M. Filippi, Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study. Neurology 82, 573-581 (2014).
9. A. Bar-Or, R. Grove, D. J. Austin, J. M. Tolson, S. A. Vanmeter, E. Lewis, P. S. Sorensen, The MIRROR study: A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the safety and MRI efficacy of subcutaneous ofatumumab in subjects with relapsing-remitting multiple sclerosis (RRMS) (S23.006). Neurology 82, S23.006 (2014).
10. A. Bar-Or, L. Fawaz, B. Fan, P.J. Darlington, A. Rieger, C. Ghorayeb, P. A. Calabresi, E. Waubant, S. L. Hauser, J. Zhang, C. H. Smith, Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann. Neurol. 67, 452-461 (2010).
11. L. Piccio, R. T. Naismith, K. Trinkaus, R. S. Klein, B.J. Parks, J. A. Lyons, A. H.Cross, Changes in B-and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch. Neurol. 67, 707-714 (2010).
12. T. A. Barr, P. Shen, S. Brown, V. Lampropoulou, T. Roch, S. Lawrie, B. Fan, R. A. O'Connor, S. M. Anderton, A. Bar-Or, S. Fillatreau, D. Gray, B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J. Exp. Med. 209, 1001-1010 (2012).
13. F. E. Lund, B. A. Garvy, T. D. Randall, D. P. Harris, Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr. Dir. Autoimmun. 8, 25-54 (2005).
14. C Mauri, A. Bosma, Immune regulatory function of Bcells.Annu. Rev. Immunol. 30, 221-241 (2012).
15. V. D. Dang, E. Hilgenberg, S. Ries, P. Shen, S. Fillatreau, From the regulatory functions of B cells to the identification of cytokine-producing plasma cell subsets. Curr. Opin. Immunol. 28, 77-83 (2014).
16. T. F. Tedder, W. J. Leonard, Autoimmunity: Regulatory B cells-IL-35 and IL-21 regulate the regulators. Nat. Rev. Rheumatol. 10, 452-453 (2014).
17. P. J. Rauch, A. Chudnovskiy, C. S. Robbins, G. F. Weber, M. Etzrodt, I. Hilgendorf, E. Tiglao, J.-L. Figueiredo, Y. Iwamoto, I. Theurl, R. Gorbatov, M. T. Waring, A. T. Chicoine, M. Mouded, M. J. Pittet, M. Nahrendorf, R. Weissleder, F. K. Swirski, Innate response activator B cells protect against microbial sepsis. Science 335, 597-601 (2012).
18. S. Fillatreau, C. H. Sweenie, M. J. McGeachy, D. Gray, S. M. Anderton, B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3, 944-950 (2002).
19. M. Duddy, M. Niino, F. Adatia, S. Hebert, M. Freedman, H. Atkins, H. J. Kim, A. Bar-Or, Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol. 178, 6092-6099 (2007).
20. T. Matsushita, K. Yanaba, J.-D. Bouaziz, M. Fujimoto, T. F. Tedder, Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118, 3420-3430 (2008).
21. P. Shen, T. Roch, V. Lampropoulou, R. A. O'Connor, U. Stervbo, E. Hilgenberg, S. Ries, V. D. Dang, Y. Jaimes, C. Daridon, R. Li, L. Jouneau, P. Boudinot, S. Wilantri, I. Sakwa, Y. Miyazaki, M. D. Leech, R. C. McPherson, S. Wirtz, M. Neurath, K. Hoehlig, E. Meinl, A. Grützkau, J. R. Grün, K. Horn, A. A. Kühl, T. Dörner, A. Bar-Or, S. H. E. Kaufmann, S. M. Anderton, S. Fillatreau, IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 507, 366-370 (2014).
22. R.-X. Wang, C.-R. Yu, I. M. Dambuza, R. M. Mahdi, M. B. Dolinska, Y. V. Sergeev, P. T. Wingfield, S.-H. Kim, C. E. Egwuagu, Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat. Med. 20, 633-641 (2014).
23. Y. Miyazaki, R. Li, A. Rezk, H. Misirliyan, C. Moore, N. Farooqi, M. Solis, L. G. Goiry, O. de Faria Junior, V. D. Dang, D. Colman, A. S. Dhaunchak, J. Antel, J. Gommerman, A. Prat, S. Fillatreau, A. Bar-Or; CIHR/MSSC New Emerging Team Grant in Clinical Autoimmunity; MSSRF Canadian B cells in MS Team, A novel microRNA-132-surtuin-1 axis underlies aberrant B-cell cytokine regulation in patients with relapsing-remitting multiple sclerosis. PLOS One 9, e105421 (2014).
24. E. C. Rosser, K. Oleinika, S. Tonon, R. Doyle, A. Bosma, N. A. Carter, K. A. Harris, S. A. Jones, N. Klein, C. Mauri, Regulatory B cells are induced by gut microbiota-driven interleukin-1b and interleukin-6 production. Nat. Med. 20, 1334-1339 (2014).
25. M. Matsumoto, A. Baba, T. Yokota, H. Nishikawa, Y. Ohkawa, H. Kayama, A. Kallies, S. L. Nutt, S. Sakaguchi, K. Takeda, T. Kurosaki, Y. Baba, Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation. Immunity 41, 1040-1051 (2014).
26. H cells. Nat. Commun. 5, 5056 (2014).
27. R. Noster, R. Riedel, M.-F. Mashreghi, H. Radbruch, L. Harms, C. Haftmann, H.-D. Chang, A. Radbruch, C. E. Zielinski, IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells. Sci. Transl. Med. 6, 241ra280 (2014).
28. A. H. Cross, J. L. Stark, J. Lauber, M. J. Ramsbottom, J.-A. Lyons, Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 180, 63-70 (2006).
29. N. Molnarfi, U. Schulze-Topphoff, M. S. Weber, J. C. Patarroyo, T. Prod'homme, M. Varrin-Doyer, A. Shetty, C. Linington, A. J. Slavin, J. Hidalgo, D. E. Jenne, H. Wekerle, R. A. Sobel, C. C. A. Bernard, M. J. Shlomchik, S. S. Zamvil, MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J. Exp. Med. 210, 2921-2937 (2013).
30. S. K. O'Neill, Y. Cao, K. M. Hamel, P. D. Doodes, G. Hutas, A. Finnegan, Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis. J. Immunol. 179, 5109-5116 (2007).
31. I. Hilgendorf, I. Theurl, L. M. S. Gerhardt, C. S. Robbins, G. F. Weber, A. Gonen, Y. Iwamoto, N. Degousee, T. A. W. Holderried, C. Winter, A. Zirlik, H. Y. Lin, G. K. Sukhova, J. Butany, B. B. Rubin, J. L. Witztum, P. Libby, M. Nahrendorf, R. Weissleder, F. K. Swirski, Innate response activator B cells aggravate atherosclerosis by stimulating T helper-1 adaptive immunity. Circulation 129, 1677-1687 (2014).
32. G. F. Weber, B. G. Chousterman, I. Hilgendorf, C. S. Robbins, I. Theurl, L. M. S. Gerhardt, Y. Iwamoto, T. D. Quach, M. Ali, J. W. Chen, T. L. Rothstein, M. Nahrendorf, R. Weissleder, F. K. Swirski, Pleural innate response activator B cells protect against pneumonia via a GM-CSF-IgM axis. J. Exp. Med. 211, 1243-1256 (2014).
33. Y. Iwata, T. Matsushita, M. Horikawa, D. J. Dilillo, K. Yanaba, G. M. Venturi, P. M. Szabolcs, S. H. Bernstein, C. M. Magro, A. D. Williams, R. P. Hall, E. W. St. Clair, T. F. Tedder, Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 117, 530-541 (2011).